Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
20 Julio 2023 - 6:03AM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage
biotechnology company developing therapies for patients with kidney
disease (the “Company” or “Unicycive”), today announced that
Shalabh Gupta, M.D., Chief Executive Officer will participate in a
fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference
“Glomerular Disease: IgAN Is Just the Tip of the Iceberg” on
Tuesday, July 25, 2023 at 11:00 a.m. ET.
A link to the live and archived webcast may be
accessed on the Unicycive website under the Investors
section: Events and Presentations. An archive of the webcast
will be available for three months.
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases.
Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a
novel investigational phosphate binding agent being developed for
the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis. UNI-494 is a patent-protected new chemical
entity in late preclinical development for the treatment of acute
kidney injury. For more information, please visit
www.unicycive.com.
SOURCE: Unicycive Therapeutics, Inc.
Investor Contact:
ir@unicycive.com
(650) 900-5470
Unicycive Therapeutics (NASDAQ:UNCY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Gráfica de Acción Histórica
De May 2023 a May 2024